Is Metagenomi, Inc. Common Stock (MGX) overvalued? · rev $25.2M
Metagenomi, Inc. Common Stock (MGX) is a biotechnology company listed on NASDAQ.
This page asks whether Metagenomi, Inc. Common Stock (MGX) looks expensive on cached numbers — not a short thesis.
Latest reported MGX revenue for 2025-12-31 was $25.2M. Net income was -$87.9M. Revenue was down 51.8% from 2024-12-31 to 2025-12-31. MGX currently screens at market cap $44.4M.
MGX currently screens at market cap $44.4M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next MGX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the MGX stock page for the full model, not this heading.
Not investment advice.